(2) Berwyn, Pennsylvania--(Newsfile Corp. - March 16, 2021) - Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing Alzheimer's disease (AD), Parkinson's disease (PD) and other neurodegenerative diseases, today announced results of an interim analysis from a double-blind, placebo-controlled study of ANVS401, its lead drug candidate for the treatment of PD and AD. Patients' speed and coordination scores both improved following 25 days of ANVS401 treatment, with no serious adverse events. Dr. Maria L. Maccecchini, CEO of Annovis Bio, explained: "We set up this study to measure the toxic cascade leading to nerve cell death and loss of function and its reversal. The study was powered to investigate a difference of 20 to 25 percent in biomarker levels, not to demonstrate efficacy, making this data that much more significant."